Background: Regulatory T (T reg ) cells have an immunosuppressive function in cancer, but the underlying mechanism of immunosuppression in the tumor microenvironment (TME) is unclear.
Background
The recent development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment. ICIs specific for anti-cytotoxic T lymphocyte antigen (CTLA)-4 or anti-programmed death (PD)-1 have improved patient survival and have been approved for the treatment of several cancer types, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, bladder cancer, and renal cell cancer [1] [2] [3] .
The tumor microenvironment (TME) and the immune system play critical roles in cancer progression and clinical outcome [4, 5] . Regulatory T (T reg ) cells are highly immunosuppressive and contribute to the maintenance of self-tolerance and immune homeostasis in humans [6, 7] . T reg cells infiltrate tumors and promote their progression by suppressing antitumor immunity in the TME. Depleting T reg cells can lead to spontaneous tumor regression due to enhanced antitumor response [7, 8] . Interaction of T reg cells with TME enhances their immunosuppressive function and proliferative capacity. Several studies have shown that tumor-infiltrating T reg cells are phenotypically distinct from those in peripheral blood (PB) and normal tissues [9, 10] , suggesting that their immunosuppressive function depends on environmental factors.
T reg cells suppressive functions are associated with the expression of several immune checkpoint molecules (ICs), such as PD-1, CTLA-4, T-cell immunoglobulin and mucin-domain containing-3 (TIM)-3, and T cell Ig and ITIM domain (TIGIT) [3, 6, [11] [12] [13] [14] . CTLA-4 and TIGIT act as tumor suppressors and thus, modulate the immune response in the TME [6, 15, 16] . Although the PD-1/PD ligand (PD-L)1 interaction was shown to promote the conversion of conventional T (T conv ) cells into T reg cells to maintain the latter's population [17] [18] [19] , it remains controversial whether PD-1 expression by T reg cells suppresses antigen-specific T cell immune responses [20] [21] [22] .
Recent studies have reported that IC-molecules are upregulated on T reg cells within the TME or upon chronic infection and that T reg cells-mediated immunosuppression correlates with the expression of ICmolecules on these cells [6, 12] . The upregulation of these molecules has also been linked to tumor progression, as it likely reinforces the suppressive function of T reg cells in the TME. We previously reported that an increased level of PD-1 on T reg cells during chronic viral infection enhances CD8 + T cell immune suppression via interaction with PD-L1 on CD8 + T cells [12] . On the contrary, high PD-1 expression on T reg cells indicates dysfunctional and exhausted IFN-γ-secreting T reg cells that are enriched in tumor infiltrates and have possibly lost their suppressive function [23] . So far, the precise role of PD-1 in the function of tumor-infiltrating T reg cells in the TME is controversial. Given the significance of PD-1 in modulating immune responses and its paradoxical role as both an activation and exhaustion marker, clarifying the function of PD-1-positive T reg cells and their role in regulating anti-tumor immune responses is important [23] .
To evaluate the suppressive function of tumorinfiltrating T reg cells in the TME, we comprehensively compared the phenotypes of T cell subsets, including T reg cells, obtained from PB, malignant effusion (ME), and tumor (TM) samples of patients with cancer. We also characterized T reg cells in paired lymphocyte samples obtained from blood, peri-tumoral tissue, and tumors of patients with lung cancer. Using a lung cancer mouse model, we investigated the suppressive function and mechanism of action of tumor-infiltrating T reg cells in the TME. We found that PD-1 was upregulated in tumor-infiltrating T reg cells and played a role in suppressing CD8 + T cell proliferation through PD-1/PD-L1 interactions. These results suggest that infiltrated PD-1-expressing T reg cells in TME are a potential therapeutic target for anti-cancer treatment.
Methods

Study design
Patients with stage IV cancer with ME and patients with cancer who planned to undergo surgical resection between April 2012 and December 2017 at the Severance Hospital were prospectively enrolled. Inclusion criteria were as follows: 1) over 20 years old; 2) stage IV cancer with malignant pleural effusion or ascites confirmed by cytology, or cancer with scheduled surgery; and 3) written informed consent. We collected 300 cc of effusions and simultaneously obtained 10 cc of PB from patients with stage IV cancer with ME, if available. In patients who underwent surgery, we collected TM-adjacent normal tissue, and 10 cc of PB to isolate peripheral blood lymphocytes (PBLs). The study was approved by the Institutional Review Board of Severance Hospital. We categorized the samples into three groups: 1) PBLs, 2) ME from patients with stage IV cancer, and 3) TM from patients with cancer who underwent surgery. To analyze the characteristics of T reg cells in TME, we also collected paired peritumoral tissue lymphocytes (pTILs), tumorinfiltrating lymphocytes (TILs), and PBLs at the same day from 12 patients with NSCLC who underwent curative resection.
Isolation of PB mononuclear cells and ME lymphocytes PB mononuclear cells were isolated from 10 cc PB collected into EDTA tubes by separation over a Percoll (Sigma-Aldrich) gradient. Lymphocytes were isolated from 500 cc of ME by discontinuous density gradient centrifugation on Percoll. To isolate TILs, lung TMs were chopped and then incubated with a solution containing 1 mg/mL collagenase type IV (Worthington Biochemical) and 0.01 mg/mL DNaseI (Sigma-Aldrich) at 37°C for 25 min. TILs were isolated by Percoll gradient after washing dissociated tissues with ice-cold RPMI1640.
Flow cytometry and antibodies
Flow cytometry was performed using a FACS CANTOII (BD Biosciences, Franklin Lakes, NJ, USA) and Cyto-FLEX (Beckman Coulter, IN, USA). Data were analyzed using FlowJo software (Tree Star, OR, USA).
For immunolabeling of human samples, fluorophoreconjugated monoclonal antibodies against the following proteins were used: CD4 (RPA-T4), CD3 (OKT3), PD-1 (EH12.2H7), and CTLA-4 (BNI3) (all from Biolegend, San Diego, CA, USA); TIM-3 (344823) and TIGIT (741182) (both from R & D Systems, Minneapolis, MN, USA); CD25 (M-A251) (BD Biosciences, Franklin Lakes, NJ, USA); and Foxp3 (PCH101) (eBioscience, San Diego, CA, USA). The LIVE/DEAD Fixable Red Dead Cell Stain kit was from Invitrogen (Carlsbad, CA, USA). T reg cells labeled with various antibodies (except for the antibody against Foxp3) were fixed and permeabilized with Foxp3 fixation/ permeabilization solution (eBioscience). Foxp3 antibody was then administered for intracellular labeling of T reg cells. The proportion of CD4 + and CD8 + T cells among total lymphocytes was determined, and the fraction of Foxp3-positive CD4 + T cells was quantified. For immunolabeling of mouse samples, fluorophoreconjugated monoclonal antibodies against the following proteins were used: CD4 (RM4-5), Ly5.1 (A20), PD-1 (29F.1A12), TIM-3 (RMT3-23), NK1.1 (PK136), and DX5 (DX5) (all from Biolegend); and CD8 (53-6.7), CD25 (PC61.5), CTLA-4 (UC10-4B9), TIGIT (G1GD7), and F4/ 80 (BM8) (all from eBioscience); and CD11b (M1/79) (BD Biosciences). The LIVE/DEAD Fixable Near-IR Dead Cell Stain kit was from Invitrogen. T reg cells labeled with various antibodies (except for the antibodies against Foxp3 and CTLA-4) were fixed and permeabilized with Foxp3 fixation/permeabilization solution (eBioscience, San Diego, CA, USA). Foxp3 antibody was then administered for intracellular labeling of T reg cells. The proportions of CD4 + and CD8 + T cells among lymphocytes were determined, and the fraction of Foxp3-positive CD4 + T cells was quantified. To prevent myeloid cells from non-specific staining, samples were preincubated with anti-CD16/32 (93) (eBioscience) before immunolabeling with fluorophoreconjugated antibodies.
Mouse TM model and lymphocyte isolation
Female C57BL/6, C57BL/6-Rag2
, and C57BL/6-Ly5.1 congenic mice (5-6 weeks) were purchased from Charles River Laboratories (Wilmington, MA, USA) and Jackson Laboratories (Bar Harbor, ME, USA). To generate lung TM bearing mice, 5 × 10 5 TC-1 cells were intravenously injected into C57BL/6 mice via the tail-vein. Mice were sacrificed on day 21 post-injection. Lymphocytes were isolated from the spleen, normal lung, and lung tumor as previously described [9] . The number of tumor nodules on left upper lobe of the lung was counted at day 12, 16, and 21 post-injection. All animal protocols were approved by the Institutional Animal Care and Use Committee of the Yonsei University Laboratory Animal Research Center (2013-0115).
In vitro suppression assay using mouse lymphocytes + T reg cells (10 6 /well) were co-cultured with CD8 + T cells (10 6 /well) with Dynabeads mouse T-activator CD3/CD28 (Thermo Fisher Scientific) in a 24-well plate at 37°C for 72 h.
For PD-1 blockade in tumor-infiltrating T reg , CD4 + CD25 + T reg cells (2.5 × 10 4 /well) isolated from tumor lymphocytes of TM bearing mice on day 14 postinjection were preincubated with 10 μg/mL anti-PD-1 antibody (RMP1-14) or rat IgG2a isotype control (2A3) (Bio X Cell) at 4°C for 1 h, washed twice, and then cocultured with CD8 + T cells (10 5 /well) in the presence of mouse T-activator CD3/CD28 Dynabeads for 68 h. ). At day 7 after cell transfer, splenocytes isolated from Rag2 −/− mice were analyzed for homeostatic expansion of the Ly5.1 + CD8 + T cell population using FACS.
In vitro suppression assay using human lymphocytes CD4 + CD25 + T reg cells were isolated from the tumor tissue and peripheral blood of NSCLC patients, using human CD4
Regulatory T Cells Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). CD8 + T cells were isolated from the paired peripheral blood of NSCLC patients using human CD8 + T Cell Isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and subsequently labeled with 5 μM CellTrace Violet. The CD8 + T cells (10 5 /well) were co-cultured with CD4 + CD25 + T reg cells (5 × 10 4 /well) isolated from either tumor tissue or peripheral blood in the presence of 2.5 μl/well of Dynabeads human T-activator CD3/28 (Thermo Fisher Scientific) at 37°C for 72 h.
Multi-color immunofluorescence analysis
For multicolor immunofluorescence analysis, lungs were isolated, fixed with 2% paraformaldehyde/phosphate buffered saline overnight at 4°C, and then embedded in OCT compound (Sakura). Tissue blocks were frozen in 2-methyl butane and cooled on dry ice. Frozen blocks were cut to a thickness of 8 μm and mounted on the silane-coated slide. Sections were stained with 4,6-diamidino-2-phenylindole (DAPI; Invitrogen) and with antibodies for anti-CD8α (Clone 53-6.7), anti-CD4 (clone RM4-5), anti-CD279 (clone RMP1-30), and anti-GFP (clone 1GFP63) for amplification of Foxp3-GFP signals (Biolegend). Streptavidinconjugated horseradish peroxidase was used for staining of biotin-conjugated antibodies, and TSA Cyanine 3 Tyramidetetramethylrhodamine reagent (SAT704A001EA; PerkinElmer) was subsequently added for amplification. Images was acquired using a microscope (Carl Zeiss Co. Ltd) and analyzed with ImageJ 1.50b software.
Statistical analysis
Data were analyzed using Prism 5.0 software (GraphPad Inc., CA, USA). The Student's t-test, one-way analysis of variance, and the least significant difference test were used, where appropriate, to evaluate the significance of differences among groups. All statistical analyses were conducted with a significance level of α = 0.05 (P < 0.05).
Results
Patient characteristics
We enrolled 103 patients: 72 were stage IV cancer patients with ME, and 31 were patients with operable disease (not stage IV) who underwent surgical resection. Detailed information of the patients from which PB, ME, or TM were obtained is described in Additional file 6: Table S1 . The total number of tumor specimens was divided into three groups based on the specimen type: PB, 20.7% (28/135); ME, 56.2% (76/135); and TM, 23.1% (31/135). Detailed analyses of immune subsets as well as the levels of their immune checkpoints were performed in PBLs (PB group), effusion-infiltrating lymphocytes (EILs) (ME group), and TILs (TM group). Primary cancer types in the ME group were NSCLC, 43.1% (31/72); gastric cancer, 22.2% (16/72); colon cancer, 5.6% (4/72), and breast cancer, 5.6% (4/72). The types of ME were ascites, 59.7% (43/76) and pleural effusion, 45.8% (33/76), with four patients having both (Additional file 6: Table  S1 ). The presence of malignant cancer cells and TILs in TM or ME was pathologically or cytologically confirmed (Fig. 1a) .
T conv with exhausted phenotypes are abundant in TM and ME To investigate T cell subsets in three different tumor specimens, we compared the ratio of CD4 + and CD8 + T cells in PBLs, EILs, and TILs isolated from PB, ME, and TM, respectively. The percentage of CD4 + T cells was higher among TILs than among PBLs or EILs. In contrast, the percentage of CD8 + T cells was markedly lower among TILs than among PBLs or EILs (Fig. 1b) , suggesting that the migration of cytotoxic lymphocytes (CTLs) into the TM was inhibited.
The phenotypes of PBLs, EILs, and TILs were compared by quantifying CD4 + and CD8 + T cells expressing PD-1 and TIM-3. The percentage of PD-1-or TIM-3-expressing CD4 + or CD8 + T cells was the highest among TILs, with lower percentages in EILs and PBLs (Fig. 1c,  d ), suggesting that T cells derived from TM and ME show more pronounced T cell exhaustion than those derived from PBLs.
High expression of PD-1 in T reg cells of ME and TM
We next examined how T reg cells expressing forkhead box (Fox) p3 are distributed and differ phenotypically in PB, ME, and TMs. T reg cells showed greater accumulation in TILs than in PBLs and EILs of patients or in PBLs of healthy controls (Fig. 2a) . Interestingly, T reg cells in TILs expressed a higher level of PD-1 than those in PBLs and EILs; moreover, the PD-1-expressing Foxp3 + population among CD4 + T cells was also larger in TILs than in EILs, which, in turn, had a larger population than PBLs (Fig. 2b) . To further characterize CD4 + T cells in different tissues, we compared PD-1 in Foxp3 + and Foxp3
− CD4 + T cells (Fig. 2c) . The proportion of PD-1-expressing cells in both CD4
+ cells was larger in EILs and TILs than in PBLs. These results indicate that PD-1 expression by T reg cells and T conv cells clearly reflect the TME, as PD-1 expression increased in the following order: TILs > EILs > PBLs.
We next investigated whether the characteristics of CD4 + T cells, CD8 + T cells, and T reg cells were altered in MEs depending on the cancer type. As shown in Additional file 1: Figure S1 , the abundance of these cells and their expression of PD-1 in MEs were comparable in different types of cancer, although it is worth noting that there were more T reg cells than there were CD4 + or CD8 + T conv cells expressing PD-1. Interestingly, the degree of infiltration of PD-1 + T reg cells did not differ among ME samples derived from the different types of cancer, indicating that the presence of PD-1 + T reg cells in ME is a common feature across cancers of distinct histological origin (Additional file 1: Figure S1 ). Additionally, we compared the phenotype of T reg between ascites and pleural effusion. As shown in Additional file 2: Figure S2 , significant differences of the percentages of Foxp3 + T reg and PD-1 + Foxp3 + T reg cells were not observed between ascites and pleural effusion. Moreover, the ascites and pleural effusions had a similar expression rate of PD-1 in Foxp3 + T reg and Foxp3 − T conv cells.
Tumor-infiltrating T reg are abundant in patients with lung cancer and express multiple IC-molecules
To clarify the characteristics of T reg cells in the TME, we compared the frequency of T reg cells and the expression of IC-molecules such as PD-1, TIM-3, TIGIT, and CTLA-4 in paired sets of tissue-derived lymphocytes, such as PBLs, pTILs, and TILs collected from 12 patients with NSCLC. As expected, T reg cells were , and tumor-infiltrating lymphocytes (TILs) were isolated from healthy control donors (HC) and patients with cancer (PBLs of HC, n = 16; PBLs, n = 28; EILs, n = 76; TILs, n = 31). Lines in the scatterplot represent the mean values. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001 (Mann-Whitney test) more highly enriched in TILs than in pTILs and PBLs (Fig. 3a) . Moreover, more T reg -expressing ICs were found among TILs than among pTILs and PBLs (Fig. 3b) .
We also compared IC-molecule expression on different tumor-infiltrating T cell subsets. Among four different IC-molecules, PD-1 most clearly distinguished TME in all T cell subsets, because a significant increase in the PD-1 + population was observed in the following order TIL > pTIL > PBL (Fig. 3c) (Fig. 3d) .
T reg numbers and the expression of IC-molecules are altered during cancer progression in a mouse model
We previously showed that immune-exhaustion markers were highly expressed in tumor-infiltrating T reg cells of patients with NSCLC. We therefore investigated the T reg phenotype in greater detail in different tissues, using a mouse lung cancer model. We compared the expression levels of IC-molecules, such as PD-1, TIM-3, and TIGIT, on CD4 + and CD8 + T cells in different tissues from naïve and TM-bearing mice. As in patients with cancer cell populations among CD4 + T cells. Peripheral blood lymphocytes (PBLs), effusion-infiltrating lymphocytes (EILs), and tumor-infiltrating lymphocytes (TILs) were isolated from healthy control donors (PBL, n = 16) and patients with cancer (PBL, n = 28; EIL, n = 76; TIL, n = 31). Lines in the scatterplot represent the mean values. ns, not significant; **P < 0.01, ***P < 0.001 (Mann-Whitney test) tissue, the expression of IC-molecules in CD4 + and CD8 + T cells was much higher in lung TM than in PB or spleen (Fig. 4a, b) . Among the populations expressing IC-molecules, PD-1-expressing CD4 + and CD8 + T cells were more abundant in the TM.
We next examined whether IC-molecules are preferentially upregulated on T reg cells (compared to T conv ) in TM, as was observed in patient tissues. PB, spleen, and lung lymphocytes were isolated at different time points after TC-1 injection (Fig. 5a ). Starting at 12 days after TC-1 injection, an increase in the number of Foxp3 + T reg cells was observed in TM and the T reg cells fraction reached 20% of total CD4 + T cells, a nearly 3-fold increase compared to that in the non-TM lung (Fig. 5b) . At 3 weeks after TC-1 injection, Foxp3 + T reg cells were more abundant in the TM than in the PB or spleen (Fig. 5c ). Foxp3 + T reg cells in TM showed significant increases in PD-1, TIM-3, TIGIT, and CTLA-4, compared to other tissues (Fig. 5d) . Moreover, tumor-infiltrating T reg cells expressed much higher levels of IC-molecules than tumor-infiltrating T conv (Fig. 5e ). Most T reg cells (8 0%), but only a low frequency of T conv (~20%) expressed PD-1 in TM. PD-1 was markedly upregulated 21 days after TC-1 injection, and the same trend was observed for TIM-3 and TIGIT, although the increases in the levels of these molecules were less prominent (Fig. 5f ). Unlike PD-1, TIM-3, and TIGIT, CTLA-4 was already upregulated in T reg cells before TC-1 injection and its expression progressively increased over time (Fig. 5f) . Thus, expression of ICmolecules, especially PD-1, on T reg cells increases Figure S4 ). Each population was co-cultured with naïve CD8 + cells with or without stimulation by αCD3/CD28. CD8 + T cells proliferated at a high rate in the absence of T reg cells and were more potently inhibited by PD-1 hi tumor-infiltrating T reg cells than by PD-1 lo spleen T reg cells (Fig. 6a) . Similarly, interferon (IFN)-γ production was also more strongly suppressed by PD-1 hi tumor-infiltrating T reg than by PD-1 lo spleen T reg cells.
To investigate the role of PD-1 upregulation, induced by tumor-infiltrating T reg cells, we examined whether the interaction between PD-1 on tumor-infiltrating T reg cells and PD-L1 on CD8 + T cells is required for immunosuppression in patients with cancer. PD-1 on tumor-infiltrating T reg cells was blocked by incubation with an anti-PD-1 antibody. Unbound antibody was subsequently removed and the cells were co-cultured with CD8 + T cells. We prepared T reg cells , expressing an intermediate level of PD-1 that were isolated from lung TM in 2-rather than in 3-weeks after injection because T reg cells , highly expressing PD-1, isolated at later timepoints, also co-expressed other IC-molecules (Fig. 5 ), making it difficult to differentiate the role of PD-1 in the suppressive function of T reg cells from that of others.
Additionally, to clarify whether the potent suppressive function of PD-1 hi tumor-infiltrating T reg cells is mediated via cell-to-cell contact between T reg and CD8 + cells or soluble factors produced from T reg cells, we conducted the experiments with transwell membrane system to block cell migration (Fig. 6b) . Transwell membranes were inserted into 24-well plate. CTV labeled CD8 + T cells and CD4 + CD25 + T reg were placed into lower and upper wells, respectively, and αCD3/CD28 was added into both wells for stimulation. Suppression of T cell proliferation was not observed in the presence of the Transwell membrane. This data demonstrated that the suppression of CD8 + T cell proliferation by T reg requires cell to cell contact between each cell population (Fig.  6b) . Next, we performed the in vivo experiment with TIL T reg and spleen T reg cellsalong with Ly5.1 + CD8 + T cells. In line with in vitro data, when TIL T reg cells was injected, CD8 + T cell proliferation was significantly LG at the tumor site. Numbers in the plot indicate percentages of the corresponding population. Data are representative of three independent experiments (n = 5 mice per group in each experiment). ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test). The symbol above each column is the P value obtained when SP samples were compared to the corresponding samples from naïve mice (control) inhibited compared with spleen T reg and no T reg cells (Fig. 6c) .
As shown in Fig. 6d , tumor-infiltrating T reg cells that had been blocked with anti-PD-1 antibody, were significantly impaired in their ability to suppress the proliferation of CD8 + T cells and IFN-γ production as compared to isotype antibody-treated tumorinfiltrating T reg cells. Given that both mouse and human CD8 + T cells can upregulate low affinity Fc receptors following activation [24, 25] , we tested whether CD8 + T cells upregulate Fc receptors in our system. We obtained splenocytes of TC-1 tumor bearing mice. We stained splenocytes with CD8, CD44, CD16/32 (FcγRIII/II), and CellTrace Violet and compared the expression of Fc receptor between with and without stimulation. Significant differences of CD16/ 32 were not observed between groups with and without stimulation (Additional file 5: Figure S5A ). To validate the CD16/32 antibody, we analyzed the expression of CD16/32 on NK cells and macrophages. This antibody can specifically detect CD16/32 on these cells, so we excluded the possibility that no detection of CD16/32 on CD8 + T cells after stimulation could be a problem of CD16/32 antibody (Additional file 5: Figure S5B ). Taken together, our data demonstrated that the effect of anti-PD-1 is direct effect by LG. e Levels of PD-1, TIM-3, TIGIT, and CTLA-4 expression on T reg and T conv in different tissues (PB, SP, and LG). f Changes in the levels of PD-1, TIM-3, TIGIT, and CTLA-4 expression on T reg at different time points. Data are representative of three independent experiments (n = 5 mice per group in each experiment). ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test) blocking of PD-1 pathway signaling rather than the effect of anti-PD-1 antibody mediated by ADCC.
A multi-color immunofluorescence analysis revealed that CD8, PD-1, and Foxp3 were co-localized in mouse tumor tissues (Fig. 6e) , implying that CD8 + cells and Foxp3 + T reg cells spatially interact in the TME.
Discussion
In this study, we examined the phenotype and function of T reg cells as well as CD4 + and CD8 + T conv cells that infiltrated into the TME, including the ME and TM from patients with cancer. We also investigated the mechanism by which T reg cells induce immunosuppression using a mouse lung cancer model. Most tumor-infiltrating T reg cells showed higher PD-1 expression than T conv cells, implying that PD-1-expressing T reg cells are a biological marker of the TME. Indeed, in T reg cells derived from TMs of patients with NSCLC, PD-1 was the most clearly upregulated IC-molecule. As previously reported, these cells exhibited an enhanced immunosuppressive function that was correlated with the extent of PD-1 upregulation [12] . We speculate that PD-1-expressing tumor-infiltrating T reg cells induce immunosuppression through the interaction of PD-1 and PD-L1, which may contribute to immune escape in TME. + T cells were stimulated as shown in (a). Before co-culture of CD8 + T cells with tumor-infiltrating T reg , the latter were pre-incubated with an anti-PD-1 antibody or its isotype as control. CTV dilution in proliferating CD8 + T cells is shown in the histograms, which represent the percentages of proliferating (upper) and IFN-γ-producing (lower) cells. (e) Representative immunofluorescence images of mouse lung tumor samples. Antibodies against Foxp3, CD8, and PD-1 were used to label and examine the interaction between T reg and CD8 + T cells expressing PD-1. Data are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test)
Clarifying the link between this phenotype and enhanced suppressive function of tumor-infiltrating T reg cells can provide insight into their suppressive mechanism in patients with cancer.
The predominant function of PD-1 in T reg cells seems to be similar to that of CTLA-4; both proteins contribute to the maintenance of T reg immunosuppressive function [15] . However, PD-1 expression on T reg cells differed by cell location. For instance, PD-1 was expressed by T reg cells in TMs but not in normal tissue or PBLs as depicted in Fig. 3 . In contrast, T reg cells had high basal CTLA-4 levels irrespective of the tissue of origin. This supports our assertion that PD-1 on T reg cells is a more useful marker for characterizing the TME. We also examined whether the upregulation of PD-1 on tumor-infiltrating T reg cells can reinforce their basal immune-suppressive function. High PD-1 expression in T reg cells was associated with the suppression of CD8 + T cells and PD-1 blockade abrogated the immunesuppressive function of T reg cells, suggesting that an interaction between PD-1 on T reg cells and PD-L1 expressed by another cell type-likely CD8 + T cells [26] -is necessary for immunosuppression. Thus, elevated PD-1 expression on T reg cells is a potential marker for immune escape in patients with cancer. These findings were consistent with our previously reported data that PD-1 upregulation in T reg cells and the interaction between PD-1 on T reg cells and PD-L1 expressed by effector T cells enhanced T cell-mediated immune suppression during chronic viral infection [12] . Thus, an immunotherapy targeting T reg and PD-1 could be highly effective in patients with cancer.
We also investigated tumor-infiltrating T reg and T conv cells obtained from ME of patients with stage IV cancer. Most of the earlier studies of TME T reg cells were performed in mice and focused on T reg cells phenotype. Studies in patients with stage IV cancer have been hampered by the difficulty of obtaining sufficient TMs for analysis of T cell populations. To overcome this limitation, we developed an experimental model using ME from human patients with stage IV cancer as representative TME of stage IV cancer. This model will allow future examinations of various mechanistic aspects of human cancer through functional assays.
Several studies have reported IC expression on intratumoral T reg cells and suggested potential roles of these ICs in the regulation of the immune response in mice [6, 15, 27] . We also showed here that ICs other than PD-1 were upregulated in T reg cells. Studies on the relative contributions of these IC-molecules to immunosuppression in the TME may lead to the development more effective immunotherapies.
Regarding other PD-1-expressing immune cells than CD8 + T cells and T reg cells in TME and their role, Irving et al. reported that tumor-associated macrophages (TAMs) expressed PD-1 and PD-1-expressing TAMs increased over time in mouse model and progressive disease in human cancers [28] . PD-1 expressed on TAMs reduced their phagocytic potency against tumor cells and blockade of PD-1 pathway restored the macrophage phagocytosis, resulting in enhancing anti-tumor activity of TAMs. This data suggests that PD-1 expressed by TAMs is one of the mechanism for immune evasion. PD-1 expression was also described on NK cells in many different types of human and mouse cancers, where the PD-1 expressed by NK cells negatively regulated NK cell function even though its molecular mechanisms are not clearly demonstrated to date [29] [30] [31] [32] [33] [34] . In addition, PD-1 has been reported to be expressed on innate lymphoid cells (ILCs), prevalently ILCs type 3 (ILC3s), as well as NK cells in pleural effusion of primary and metastatic tumors, albeit the role of PD-1 on ILC3s was not addressed [35] . Based on these reports, it is plausible that PD-1 expressed by different types of immune cells including CD8+ T cells, T reg cells, NK cells, and ILCs in the TME probably contributes to immune evasion, leading to promotion of tumor cells. However, it has not been addressed yet which types of PD-1-expressing immune cells are most effectively involved in the PD-1-mediated immunosuppression. In addition, to compare the immunosuppressive activity of each immune cell subset, the level of PD-1 expression on each type of cells should be examined. In this regard, further study is needed to determine whether other PD-1-expressing immune cells than T reg cells in the TME compensate for a lack of T reg cells and which types of PD-1-expressing immune cells mostly impact on immune suppression in the TME.
T reg cells expansion in the TME is widely recognized as an obstacle to successful immunotherapy in patients with cancer [5] . Previously, we demonstrated that T reg cells depletion using an anti-CD25 antibody increased the abundance of functional antigen-specific CD8 + T cells during chronic viral infection [12] . Furthermore, treatment with a neutralizing antibody also caused the elimination of non-T reg and rapid replenishment of T reg cells [36] . Thus, functional inactivation of T reg cells and rejuvenation of exhausted T cells by targeting overexpressed PD-1 combined with temporal depletion of T reg cells expressing IC-molecules may be a promising strategy to limit cancer progression.
Conclusions
In conclusion, our study provides insights into T reg cells function and their suppressive mechanism in patients with cancer. We showed that the suppressive function of tumor-infiltrating T reg cells was enhanced by the increase in their relative proportion and by the upregulation of the expression of inhibitory receptors, such as PD-1, TIM-3, and CTLA-4.
